top of page

The CEO of Maze Therapeutics' shares his perspective on FTC's scuttling of his company's licensing deal with Sanofi

Jason Coloma shares the smaller company's perspective of how a licensing deal was scuttled by the FTC and what it might mean for the broader industry. He also introduces us to Maze's approach and programs.




Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page